Endovia Health Sciences (EDVA) Cash & Equivalents Growth (3y) (2014 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Cash & Equivalents Growth (3y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | -27.97% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -3.85% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | -35.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35.47% |
| Mar 31, 2026 | -43.78% |
| Dec 31, 2025 | -60.10% |
| Sep 30, 2025 | -53.26% |
| Jun 30, 2025 | -84.00% |
| Dec 31, 2024 | -85.12% |
| Sep 30, 2024 | -61.72% |
| Jun 30, 2024 | -91.14% |
| Mar 31, 2024 | -77.08% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | -49.69% |
| Jun 30, 2023 | 96.66% |
| Mar 31, 2023 | 51.26% |
| Dec 31, 2022 | 370.17% |
| Sep 30, 2022 | 340.83% |
| Jun 30, 2022 | 292.73% |
| Mar 31, 2022 | 211.25% |
| Dec 31, 2021 | 64.58% |
| Sep 30, 2021 | 621.54% |
| Jun 30, 2021 | 610.52% |